Tempest Therapeutics is actively transforming its operational approach to advance its oncology drug pipeline and manage complex clinical development programs. The company prioritizes streamlining clinical data management systems and integrating diverse research data platforms to accelerate drug discovery and development. This focused digital shift supports their mission of delivering first-in-class cancer therapies more efficiently.
This transformation creates critical dependencies on robust data integrity and seamless system interoperability across its research, clinical, and regulatory functions. Potential breakdowns include inconsistent data across various clinical sites and manual processes hindering regulatory compliance. This page will analyze Tempest Therapeutics’ specific digital initiatives, the operational challenges they face, and where sellers can engage effectively.
Tempest Therapeutics Snapshot
Headquarters: Brisbane, California, United States
Number of employees: 1-10 employees
Public or private: Public
Business model: B2B
Website: http://www.tempesttx.com
Tempest Therapeutics ICP and Buying Roles
Tempest Therapeutics sells to organizations requiring advanced oncology therapeutics for clinical development.
The company targets complex scientific challenges in cancer treatment, not basic research applications.
Who drives buying decisions
- Head of Clinical Operations → Directs clinical trial execution and data integrity
- Head of Research & Development → Oversees preclinical studies and data insights
- Head of Regulatory Affairs → Manages agency submissions and compliance
- Chief Scientific Officer → Establishes scientific strategy and technology adoption
- Alliance Manager → Coordinates external partner collaborations and data exchange
Key Digital Transformation Initiatives at Tempest Therapeutics (At a Glance)
- Optimizing Clinical Data Management Systems for trial execution
- Integrating Research Data Platforms for drug discovery
- Implementing Regulatory Information Management Systems for compliance
- Establishing Collaborative Partner Data Exchange for co-development programs
- Digitizing CAR-T Manufacturing Processes for quality control
Where Tempest Therapeutics’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| Clinical Data Management Platforms | Clinical Data Management System Optimization: inconsistent data formats block real-time analysis across trial sites | Head of Clinical Operations, Clinical Data Manager | Standardize data capture and validation across diverse clinical studies |
| Clinical Data Management System Optimization: manual reconciliation delays database lock | Clinical Data Manager, Biostatistician | Automate data reconciliation workflows before final database lock | |
| Clinical Data Management System Optimization: data discrepancies occur during partner data transfers | Alliance Manager, Clinical Data Manager | Enforce data standardization rules for external partner data ingestion | |
| Research Data Integration Platforms | Research Data Integration Platform: disconnected data sources prevent comprehensive target identification | Head of Research & Development, Bioinformatics Lead | Consolidate disparate preclinical and R&D data into a unified repository |
| Research Data Integration Platform: manual data aggregation delays scientific insights | Bioinformatics Lead, Data Scientist | Route research data automatically from lab instruments into analysis pipelines | |
| Research Data Integration Platform: missing metadata blocks data reusability for new studies | Data Scientist, Head of Research & Development | Validate metadata completeness during data ingestion for future analysis | |
| Regulatory Information Management Systems | Regulatory Information Management System Implementation: document version control creates submission errors for agency filings | Head of Regulatory Affairs, Regulatory Operations Manager | Enforce consistent document versioning across all regulatory artifacts |
| Regulatory Information Management System Implementation: manual tracking of commitments causes compliance gaps | Regulatory Operations Manager, Quality Assurance Lead | Detect deviations from regulatory commitments in real-time | |
| Regulatory Information Management System Implementation: dispersed documentation delays audit responses | Quality Assurance Lead, Head of Regulatory Affairs | Standardize document retrieval for swift audit responses | |
| Secure Data Exchange Platforms | Collaborative Partner Data Exchange: insecure file transfer methods expose sensitive intellectual property | IT Security Lead, Alliance Manager | Encrypt data transfers and control access permissions for external collaborations |
| Collaborative Partner Data Exchange: incompatible data structures block efficient partner data ingestion | Alliance Manager, Clinical Data Manager | Standardize data schema alignment with co-development partners | |
| CAR-T Manufacturing Digitization | CAR-T Manufacturing Process Digitization: manual batch record generation introduces data entry errors during cell processing | Head of Manufacturing, Quality Control Manager | Automate data capture for batch records in cell manufacturing |
| CAR-T Manufacturing Process Digitization: inconsistent chain of custody tracking complicates audit readiness | Quality Control Manager, Process Engineer | Enforce digital chain of custody across the manufacturing workflow |
Identify when companies like Tempest Therapeutics are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Tempest Therapeutics’s digital transformation unique
Tempest Therapeutics prioritizes digital transformation specifically to support a capital-efficient R&D model, relying heavily on external partnerships and collaborations for clinical advancement. This approach means their digital infrastructure must facilitate secure, compliant, and efficient data exchange with partners like Novatim Immune Therapeutics and the National Cancer Institute. Their transformation is deeply tied to managing complex clinical trials and CAR-T manufacturing with constrained internal resources, forcing precise system selections that enable robust compliance and data integrity across distributed operations.
Tempest Therapeutics’s Digital Transformation: Operational Breakdown
DT Initiative 1: Clinical Data Management System Optimization
What the company is doing
Tempest Therapeutics standardizes data capture and analysis within ongoing global clinical trials. This includes managing information from Phase 1, Phase 2, and future Phase 3 studies for multiple drug candidates. The company implements systems to handle diverse clinical data types and reporting requirements.
Who owns this
- Head of Clinical Operations
- Clinical Data Manager
- Biostatistician
Where It Fails
- Inconsistent data formats block real-time analysis across trial sites.
- Manual reconciliation delays database lock for clinical studies.
- Data discrepancies occur during partner data transfers for co-development programs.
Talk track
Noticed Tempest Therapeutics is managing complex clinical trial data. Been looking at how some biotech teams are standardizing data schemas upfront instead of fixing errors during analysis, can share what’s working if useful.
DT Initiative 2: Research Data Integration Platform
What the company is doing
Tempest Therapeutics consolidates disparate preclinical and R&D data sources to accelerate drug discovery initiatives. This involves centralizing information from laboratory experiments and bioinformatics analyses. The company builds unified platforms to generate novel scientific insights from this integrated data.
Who owns this
- Head of Research & Development
- Bioinformatics Lead
- Data Scientist
Where It Fails
- Disconnected data sources prevent comprehensive target identification.
- Manual data aggregation delays scientific insights from preclinical studies.
- Missing metadata blocks data reusability for new research initiatives.
Talk track
Saw Tempest Therapeutics is integrating diverse research data. Been looking at how some R&D teams are enforcing metadata standards early instead of restructuring data for each analysis, happy to share what we’re seeing.
DT Initiative 3: Regulatory Information Management System (RIMS) Implementation
What the company is doing
Tempest Therapeutics centralizes regulatory submissions and documentation for interactions with agencies like the FDA and EMA. This includes managing records for Orphan Drug and Fast Track designations. The company implements systems to streamline compliance and reporting processes.
Who owns this
- Head of Regulatory Affairs
- Regulatory Operations Manager
- Quality Assurance Lead
Where It Fails
- Document version control creates submission errors for agency filings.
- Manual tracking of regulatory commitments causes compliance gaps.
- Dispersed documentation delays audit responses from regulatory bodies.
Talk track
Looks like Tempest Therapeutics is managing critical regulatory submissions. Been seeing teams automate document versioning instead of manual checks, can share what’s working if useful.
DT Initiative 4: Collaborative Partner Data Exchange
What the company is doing
Tempest Therapeutics establishes secure data sharing protocols with external co-development partners. This supports their strategy of advancing the pipeline through partner-funded and externally supported programs. The company builds mechanisms for efficient data transfer and collaboration with entities like Novatim Immune Therapeutics.
Who owns this
- Head of Business Development
- Alliance Manager
- IT Security Lead
Where It Fails
- Insecure file transfer methods expose sensitive intellectual property.
- Incompatible data structures block efficient partner data ingestion.
- Lack of audit trails prevents tracking data access by external collaborators.
Talk track
Noticed Tempest Therapeutics is collaborating extensively with partners. Been looking at how some biotech companies are standardizing data exchange contracts upfront instead of manual data mapping post-agreement, happy to share what we’re seeing.
DT Initiative 5: CAR-T Manufacturing Process Digitization
What the company is doing
Tempest Therapeutics digitizes quality control and chain of custody tracking for its CAR-T cell therapy manufacturing processes. This supports the development of acquired dual-targeting CAR-T assets like TPST-2003 and TPST-4003. The company implements systems to ensure product integrity and audit readiness.
Who owns this
- Head of Manufacturing
- Quality Control Manager
- Process Engineer
Where It Fails
- Manual batch record generation introduces data entry errors during cell processing.
- Inconsistent chain of custody tracking complicates audit readiness for cell therapies.
- Disconnected equipment data delays real-time process monitoring during manufacturing.
Talk track
Saw Tempest Therapeutics is scaling CAR-T manufacturing. Been seeing teams digitize batch record approvals instead of relying on paper processes, can share what’s working if useful.
Who Should Target Tempest Therapeutics Right Now
This account is relevant for:
- Clinical Data Management System providers
- Research Data Integration platforms
- Regulatory Information Management System vendors
- Secure Data Exchange solutions
- CAR-T Manufacturing Execution Systems
Not a fit for:
- Generic HR or payroll software
- Basic marketing automation platforms
- Standalone website builders
- Commodity IT infrastructure providers
When Tempest Therapeutics Is Worth Prioritizing
Prioritize if:
- You sell solutions that enforce data standardization across global clinical trials
- You sell platforms that consolidate disparate preclinical and R&D data into a unified view
- You sell systems that automate document versioning for regulatory submissions
- You sell secure data exchange platforms with robust audit trails for external partners
- You sell solutions that digitize batch record generation and chain of custody for cell manufacturing
Deprioritize if:
- Your solution does not address any of the breakdowns above
- Your product is limited to basic functionality with no integration capabilities
- Your offering is not built for complex scientific data or regulated environments
Who Can Sell to Tempest Therapeutics Right Now
Clinical Data Management Platforms
Veeva Systems - This company provides cloud-based software for the life sciences industry, focusing on clinical, regulatory, quality, and commercial operations.
Why they are relevant: Inconsistent data formats block real-time analysis across Tempest Therapeutics’ clinical trial sites. Veeva Clinical Operations Suite can standardize data capture and enforce consistent data schemas across studies, preventing reconciliation delays and data discrepancies during partner transfers.
Medidata Solutions - This company offers a unified platform for clinical research, providing solutions for clinical trial planning, management, and execution.
Why they are relevant: Manual reconciliation delays database lock in Tempest Therapeutics’ clinical studies. Medidata Rave Clinical Cloud can automate data collection and validation workflows, reducing manual effort and accelerating the time to database lock for critical trial results.
Research Data Integration Platforms
Benchling - This company offers a cloud-native informatics platform that helps life science R&D organizations manage their experiments, samples, and data.
Why they are relevant: Disconnected data sources prevent comprehensive target identification in Tempest Therapeutics’ R&D. Benchling's R&D Cloud can centralize preclinical and laboratory data, providing a unified view that facilitates novel scientific insights and improves data reusability.
Dotmatics - This company provides scientific software solutions that integrate R&D data, workflows, and analytics for chemistry and biology research.
Why they are relevant: Manual data aggregation delays scientific insights from preclinical studies at Tempest Therapeutics. Dotmatics' platform can automate the routing of research data from lab instruments into analysis pipelines, ensuring real-time access to information for data scientists and researchers.
Regulatory Information Management (RIM) Systems
Extedo - This company offers software solutions for regulatory information management, pharmacovigilance, and document management in the life sciences.
Why they are relevant: Document version control creates submission errors for agency filings at Tempest Therapeutics. Extedo's eCTDmanager and other RIM solutions can enforce consistent document versioning and formatting, preventing compliance gaps and streamlining regulatory submissions to FDA and EMA.
ArisGlobal - This company provides cloud-based software solutions for drug development, with modules for pharmacovigilance, clinical development, regulatory affairs, and quality management.
Why they are relevant: Manual tracking of regulatory commitments causes compliance gaps for Tempest Therapeutics. ArisGlobal's LifeSphere Regulatory can detect deviations from regulatory commitments in real-time and centralize documentation, improving audit readiness and response times for regulatory bodies.
Secure Data Exchange Platforms
Egnyte - This company offers a cloud content governance platform that provides secure file sharing, collaboration, and data protection, particularly for regulated industries.
Why they are relevant: Insecure file transfer methods expose sensitive intellectual property during partner data exchange at Tempest Therapeutics. Egnyte can encrypt data transfers and enforce granular access permissions, protecting critical research and clinical data shared with co-development partners.
Kiteworks - This company provides a content firewall that secures the exchange of sensitive information, offering controlled access and auditing for enterprise content.
Why they are relevant: Incompatible data structures block efficient partner data ingestion at Tempest Therapeutics. Kiteworks can standardize data schema alignment with co-development partners, ensuring secure and efficient transfer of clinical and manufacturing data for collaborative programs.
Final Take
Tempest Therapeutics scales complex clinical trials and CAR-T manufacturing, generating significant data across global partnerships. Breakdowns are visible in manual data reconciliation, inconsistent document versioning for regulatory filings, and insecure data exchange with external collaborators. This account is a strong fit for solutions that enforce data integrity, automate compliance workflows, and secure partner data environments within a capital-efficient framework.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.